{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T21:55:16Z","timestamp":1794002116587,"version":"4.8.0"},"reference-count":24,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100020956","name":"Merck Healthcare KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100020956","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annalsofoncology.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Oncology"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.annonc.2025.05.010","type":"journal-article","created":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T10:47:44Z","timestamp":1748774864000},"page":"1088-1095","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"title":["Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis"],"prefix":"10.1016","volume":"36","author":[{"given":"J.","family":"Hoffman-Censits","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Tsiatas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.M.-H.","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Antonuzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.J.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Gakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Blais","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.A.","family":"Arranz Arija","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.L.","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Zagouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Maruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Tournigand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Forget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schneider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Tyroller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Grivas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.P.","family":"Valderrama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"19","key":"10.1016\/j.annonc.2025.05.010_bib1","doi-asserted-by":"crossref","first-page":"3486","DOI":"10.1200\/JCO.22.01792","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: results from the JAVELIN Bladder 100 trial after \u22652 years of follow-up","volume":"41","author":"Powles","year":"2023","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.annonc.2025.05.010_bib2","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1056\/NEJMoa2002788","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.010_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/j.eururo.2022.04.016","article-title":"Patient-reported outcomes from JAVELIN Bladder 100: avelumab first-line maintenance plus best supportive care versus best supportive care alone for advanced urothelial carcinoma","volume":"83","author":"Grivas","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.05.010_bib4","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2025.04.004","article-title":"Avelumab first-line maintenance for advanced urothelial carcinoma: long-term analyses of patient-reported outcomes and quality-adjusted time without symptoms or toxicity from the JAVELIN Bladder 100 trial","author":"Grivas","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.010_bib5","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/j.annonc.2021.11.012","article-title":"Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"33","author":"Powles","year":"2022","journal-title":"Ann Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.05.010_bib6","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.annonc.2024.03.001","article-title":"ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma","volume":"35","author":"Powles","year":"2024","journal-title":"Ann Oncol"},{"issue":"1","key":"10.1016\/j.annonc.2025.05.010_bib7","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.eururo.2021.09.026","article-title":"The 2021 updated European Association of Urology guidelines on metastatic urothelial carcinoma","volume":"81","author":"Cathomas","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.annonc.2025.05.010_bib8","series-title":"Bladder Cancer. v6","year":"2024"},{"key":"10.1016\/j.annonc.2025.05.010_bib13","article-title":"Summary of product characteristics","year":"2023","journal-title":"Gilead Sciences Ireland UC, Carrigtwohill, Co., Cork, Ireland"},{"key":"10.1016\/j.annonc.2025.05.010_bib14","series-title":"Prescribing information","year":"2024"},{"issue":"12","key":"10.1016\/j.annonc.2025.05.010_bib15","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1200\/JCO.22.02835","article-title":"Sacituzumab govitecan in combination with pembrolizumab for patients with metastatic urothelial cancer that progressed after platinum-based chemotherapy: TROPHY-U-01 cohort 3","volume":"42","author":"Grivas","year":"2024","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.010_bib16","doi-asserted-by":"crossref","first-page":"179","DOI":"10.2217\/fon-2023-0492","article-title":"The JAVELIN Bladder Medley trial: avelumab-based combinations as first-line maintenance in advanced urothelial carcinoma","volume":"20","author":"Hoffman-Censits","year":"2024","journal-title":"Future Oncol"},{"issue":"3","key":"10.1016\/j.annonc.2025.05.010_bib17","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/00273171.2011.568786","article-title":"An introduction to propensity score methods for reducing the effects of confounding in observational studies","volume":"46","author":"Austin","year":"2011","journal-title":"Multivariate Behav Res"},{"key":"10.1016\/j.annonc.2025.05.010_bib18","first-page":"11","article-title":"A tool for assessing the feasibility of comparative effectiveness research","volume":"3","author":"Walker","year":"2013","journal-title":"Comp Eff Res"},{"key":"10.1016\/j.annonc.2025.05.010_bib19","article-title":"READY: REAl-world Data from an Italian compassionate use program of avelumab first-line maintenance for locallY advanced or metastatic urothelial carcinoma","volume":"5","author":"Antonuzzo","year":"2024","journal-title":"ESMO Real World Data Dig Oncol"},{"issue":"6","key":"10.1016\/j.annonc.2025.05.010_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2024.102238","article-title":"Avelumab first-line maintenance for locally advanced or metastatic urothelial carcinoma: results from the real-world US PATRIOT-II study","volume":"22","author":"Grivas","year":"2024","journal-title":"Clin Genitourin Cancer"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.010_bib21","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/j.euo.2024.09.014","article-title":"Real-world study of avelumab first-line maintenance treatment in patients with advanced urothelial carcinoma in France: overall results from the noninterventional AVENANCE study and analysis of outcomes by second-line treatment","volume":"8","author":"Barthelemy","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"9","key":"10.1016\/j.annonc.2025.05.010_bib22","doi-asserted-by":"crossref","first-page":"5662","DOI":"10.3390\/curroncol31090420","article-title":"Real-world treatment patterns, sequencing, and outcomes in patients with locally advanced or metastatic urothelial carcinoma receiving avelumab first-line maintenance in the United States","volume":"31","author":"Moon","year":"2024","journal-title":"Curr Oncol"},{"issue":"suppl 16","key":"10.1016\/j.annonc.2025.05.010_bib23","article-title":"Real-world (rw) treatment (tx) patterns, sequencing, and outcomes in US patients (pts) with locally advanced or metastatic urothelial cancer (la\/mUC) treated with avelumab first-line maintenance (1LM)","volume":"42","author":"Carson","year":"2024","journal-title":"J Clin Oncol"},{"issue":"suppl 5","key":"10.1016\/j.annonc.2025.05.010_bib24","article-title":"Real-world effectiveness and treatment (tx) patterns in patients (pts) with locally advanced\/metastatic urothelial carcinoma (la\/mUC) receiving avelumab first-line maintenance (1LM) in Japan: results from the JAVEMACS chart review study","volume":"43","author":"Kitamura","year":"2025","journal-title":"J Clin Oncol"},{"issue":"29","key":"10.1016\/j.annonc.2025.05.010_bib25","doi-asserted-by":"crossref","first-page":"3410","DOI":"10.1200\/JCO.23.01720","article-title":"TROPHY-U-01 cohort 2: a phase II study of sacituzumab govitecan in cisplatin-ineligible patients with metastatic urothelial cancer progressing after previous checkpoint inhibitor therapy","volume":"42","author":"Petrylak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.annonc.2025.05.010_bib26","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/cpt.3495","article-title":"Exposure-response analyses of sacituzumab govitecan efficacy and safety in patients with metastatic triple-negative breast cancer","volume":"117","author":"Sathe","year":"2025","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.annonc.2025.05.010_bib27","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann Oncol"},{"issue":"4","key":"10.1016\/j.annonc.2025.05.010_bib28","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.annonc.2024.01.002","article-title":"TROPHY-U-01, a phase II open-label study of sacituzumab govitecan in patients with metastatic urothelial carcinoma progressing after platinum-based chemotherapy and checkpoint inhibitors: updated safety and efficacy outcomes","volume":"35","author":"Loriot","year":"2024","journal-title":"Ann Oncol"}],"container-title":["Annals of Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425002029?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0923753425002029?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T05:14:31Z","timestamp":1762319671000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0923753425002029"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["S0923753425002029"],"URL":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.010","relation":{},"ISSN":["0923-7534"],"issn-type":[{"value":"0923-7534","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Avelumab plus sacituzumab govitecan versus avelumab monotherapy as first-line maintenance treatment in patients with advanced urothelial carcinoma: JAVELIN Bladder Medley interim analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annonc.2025.05.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}]}}